TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6140699

Group type: EXPERIMENTAL
Intervention: Ethanol 0.4 g/kg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nitrazepam 5 mg + Placebo (Ethanol 0.1 g/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg + Ethanol 0.2 g/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg + Ethanol 0.4 g/kg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Temazepam 20 mg + Placebo (Ethanol 0.1 g/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg + Ethanol 0.2 g/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg + Ethanol 0.4 g/kg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ethanol alone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg
Number of subjects: 10
Study: 31092643

Group type: EXPERIMENTAL
Intervention: MyHeartMate app intervention
Number of subjects: 394

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 394
Study: 29467465

Group type: EXPERIMENTAL
Intervention: Primary total knee replacement (TKR) surgery
Number of subjects: 2244
Study: 27600257

Group type: EXPERIMENTAL
Intervention: Permethrin 5% topical gel
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 25246421

Group type: EXPERIMENTAL
Intervention: Deep-fried Mars bar
Number of subjects: 24

Group type: COMPARATOR
Intervention: Porridge (control)
Number of subjects: 24
Study: 22808165

Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 20542800

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stents (ZES)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 46
Study: 18844012

Group type: EXPERIMENTAL
Intervention: AcrySof ReStor MIOL
Number of subjects: 60

Group type: COMPARATOR
Intervention: Single focal intraocular lens (SIOL)
Number of subjects: 60
Study: 15905672

Group type: EXPERIMENTAL
Intervention: Efavirenz
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Nevirapine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Abacavir
Number of subjects: 90
Study: 12021827

Group type: EXPERIMENTAL
Intervention: Citicoline 500 mg orally once daily for 6 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Citicoline continued for a second 6-week period
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9892879

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg once daily for 4 or 8 weeks
Number of subjects: 202

Group type: COMPARATOR
Intervention: Omeprazole 20 mg once daily for 4 or 8 weeks
Number of subjects: 202
Study: 7707258

Group type: EXPERIMENTAL
Intervention: Listening to music
Number of subjects: 0

Group type: COMPARATOR
Intervention: No music (control group)
Number of subjects: 0
Study: 3374808

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (50 mg of starch)
Number of subjects: 0
Study: 29278278

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Linaclotide 0.0625 mg
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Linaclotide 0.125 mg
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Linaclotide 0.25 mg
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Linaclotide 0.5 mg
Number of subjects: 559
Study: 27367422

Group type: EXPERIMENTAL
Intervention: Computer-Based Training (CBT) of the modified Fones technique
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Computer-Based Training (CBT) of the modified Bass technique
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (C) with no further instructions
Number of subjects: 93
Study: 24901956

Group type: EXPERIMENTAL
Intervention: Personalized care (PC)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 81
Study: 22245919

Group type: EXPERIMENTAL
Intervention: Danish national return-to-work program (RTW)
Number of subjects: 19500
Study: 20630890

Group type: EXPERIMENTAL
Intervention: Xenon 60% with remifentanil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sevoflurane 2.0% with remifentanil
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Xenon 60%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sevoflurane 2.0%
Number of subjects: 60
Study: 17596905

Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 268

Group type: COMPARATOR
Intervention: Buprenorphine/naloxone or Methadone
Number of subjects: 268
Study: 15839590

Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD) + bioactive glass (BG)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Bioactive glass (BG) alone
Number of subjects: 6
Study: 12417358

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10616013

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg/day)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Nifedipine (40 mg/day)
Number of subjects: 52
Study: 9026280

Group type: EXPERIMENTAL
Intervention: Low dose GnRH agonist
Number of subjects: 2

Group type: COMPARATOR
Intervention: Long protocol with GnRH agonist in depot formula
Number of subjects: 2
Study: 2055292

Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF)
Number of subjects: 20
Study: 6667808

Group type: EXPERIMENTAL
Intervention: Ibopamine 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ibopamine 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ibopamine 150 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30817764

Group type: EXPERIMENTAL
Intervention: Patterned, frequency-modulated oral stimulation via the NTrainer system through a pulsatile pacifier
Number of subjects: 210

Group type: COMPARATOR
Intervention: Non-pulsatile pacifier
Number of subjects: 210
Study: 28572492

Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 8
Study: 27020655

Group type: EXPERIMENTAL
Intervention: anti-H. pylori
Number of subjects: 809

Group type: EXPERIMENTAL
Intervention: celecoxib
Number of subjects: 809

Group type: EXPERIMENTAL
Intervention: anti-H. pylori followed by celecoxib
Number of subjects: 809

Group type: EXPERIMENTAL
Intervention: subjects with decreased COX‐2 methylation levels
Number of subjects: 809
Study: 24697925

Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Oral acetaminophen
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (intravenous/oral placebo)
Number of subjects: 45
Study: 23067089

Group type: COMPARATOR
Intervention: Clobetasol propionate 0.05% ointment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment
Number of subjects: 40
Study: 19348540

Group type: EXPERIMENTAL
Intervention: Negative expectations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Positive expectations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Event occurrence
Number of subjects: 0
Study: 17419886

Group type: EXPERIMENTAL
Intervention: KVIQ-20
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: KVIQ-10
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: KVIQ-20 (imagining movements of affected limbs)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: KVIQ-20 (imagining movements of unaffected limbs)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: KVIQ-10 (imagining movement of dominant limbs)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: KVIQ-10 (imagining movement of nondominant limbs)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: KVIQ-20 and KVIQ-10
Number of subjects: 65
Study: 14997006

Group type: EXPERIMENTAL
Intervention: Anakinra therapy
Number of subjects: 1007

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1007
Study: 12352776

Group type: EXPERIMENTAL
Intervention: 20-week Arthritis Foundation aquatic exercise program (n = 125)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Wait-list control group (n = 124)
Number of subjects: 249
Study: 9828849

Group type: EXPERIMENTAL
Intervention: auto-CPAP treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: conventional CPAP treatment
Number of subjects: 16
Study: 7536205

Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 11
Study: 2263585

Group type: EXPERIMENTAL
Intervention: Free running group
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Swimming group
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 6210722

Group type: EXPERIMENTAL
Intervention: Desipramine (DMI), mean maximum daily dose 283 mg (range 100-400 mg/d)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Clomipramine (CMI)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Desipramine (DMI)
Number of subjects: 34
Study: 31707465

Group type: EXPERIMENTAL
Intervention: Romosozumab (210 mg once monthly)
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Teriparatide (20 µg once daily)
Number of subjects: 436
Study: 30321602

Group type: EXPERIMENTAL
Intervention: PFJ OA participants
Number of subjects: 64
Study: 28153659

Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg (4000 IU) by subcutaneous injection daily from recruitment until 36+0 weeks or delivery
Number of subjects: 156

Group type: COMPARATOR
Intervention: Standard high-risk care only
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 156
Study: 25305357

Group type: EXPERIMENTAL
Intervention: Transvaginal polypropylene mesh insertion
Number of subjects: 100

Group type: COMPARATOR
Intervention: Anterior colporrhaphy
Number of subjects: 100
Study: 25512817

Group type: EXPERIMENTAL
Intervention: Urodynamic testing group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Office evaluation only group
Number of subjects: 60
Study: 22784845

Group type: EXPERIMENTAL
Intervention: 400 IU vitamin D3 daily for 6 months
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 2,000 IU vitamin D3 daily for 6 months
Number of subjects: 105
Study: 18979150

Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg/kg every 4 weeks plus MTX placebo
Number of subjects: 125

Group type: COMPARATOR
Intervention: Tocilizumab placebo plus MTX 8 mg/week
Number of subjects: 125
Study: 16798061

Group type: EXPERIMENTAL
Intervention: Bethanechol during radiotherapy
Number of subjects: 43

Group type: COMPARATOR
Intervention: Artificial saliva (control group)
Number of subjects: 43
Study: 15357025

Group type: EXPERIMENTAL
Intervention: MML (sn-1(3),2) fat load
Number of subjects: 10

Group type: COMPARATOR
Intervention: MLM (sn-1,3) fat load
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both fat loads
Number of subjects: 10
Study: 11603877

Group type: EXPERIMENTAL
Intervention: Cancer education program for clergy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 9689271

Group type: EXPERIMENTAL
Intervention: Isoflurane 0.6-0.8 vol%
Number of subjects: 556

Group type: COMPARATOR
Intervention: Halothane 0.4-0.6 vol%
Number of subjects: 556

Group type: COMPARATOR
Intervention: Enflurane 0.8-1 vol%
Number of subjects: 556
Study: 7806832

Group type: EXPERIMENTAL
Intervention: 3 MU of i.m. recombinant IFN‐alpha 2a three times per week for 3 months (group A)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 3 MU of i.m. recombinant IFN‐alpha 2a three times per week for 6 months (group B)
Number of subjects: 62
Study: 2691694

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no antihypertensive treatment)
Number of subjects: 0
Study: 1190102

Group type: EXPERIMENTAL
Intervention: Daily administration of 2 g of vitamin C
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31127479

Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin and carboplatin (PLDC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Gemcitabine and carboplatin (GC)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Gemcitabine
Number of subjects: 100
Study: 29927558

Group type: EXPERIMENTAL
Intervention: Vitamin D3 1,800 IU/d supplementation for 6 weeks
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 26213879

Group type: EXPERIMENTAL
Intervention: Analgesic administration with massage
Number of subjects: 25

Group type: COMPARATOR
Intervention: Analgesic administration alone
Number of subjects: 25
Study: 23580740

Group type: EXPERIMENTAL
Intervention: Single dose of methylphenidate (MPH)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 30
Study: 21385483

Group type: EXPERIMENTAL
Intervention: Disposable biopsy needle guide
Number of subjects: 55

Group type: COMPARATOR
Intervention: Reusable biopsy needle guide
Number of subjects: 55
Study: 19670953

Group type: EXPERIMENTAL
Intervention: CPCRS care
Number of subjects: 421

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 421
Study: 17868717

Group type: EXPERIMENTAL
Intervention: Brachytherapy with a highest dose covering at least 90% of the prostate of 100% or greater
Number of subjects: 568
Study: 14962409

Group type: EXPERIMENTAL
Intervention: HRT topographic optic disk measurements
Number of subjects: 439
Study: 11347755

Group type: EXPERIMENTAL
Intervention: 1.25 mg ramipril
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 5.0 mg ramipril
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 9232976

Group type: EXPERIMENTAL
Intervention: Weighted march activity
Number of subjects: 350

Group type: COMPARATOR
Intervention: Standard recruit training program (running)
Number of subjects: 350
Study: 8329830

Group type: EXPERIMENTAL
Intervention: GHRH(1-29)-NH2, 30 micrograms/kg/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: GHRH(1-29)-NH2, 60 micrograms/kg/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: GH, 0.1 IU/kg/day
Number of subjects: 60
Study: 3540222

Group type: EXPERIMENTAL
Intervention: Sustained-release verapamil (240 mg tablets, twice daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Instant-release verapamil (80 mg tablets, 160 mg twice daily)
Number of subjects: 24
Study: 31197867

Group type: EXPERIMENTAL
Intervention: IMSI
Number of subjects: 150

Group type: COMPARATOR
Intervention: ICSI
Number of subjects: 150
Study: 28222579

Group type: EXPERIMENTAL
Intervention: Small-sided game (SSG) training intervention for 6 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both experimental and control groups
Number of subjects: 23
Study: 27417317

Group type: EXPERIMENTAL
Intervention: Cabazitaxel (20 mg/m² every 3 weeks)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Cabazitaxel (8.4 mg/m² weekly)
Number of subjects: 28
Study: 24813808

Group type: EXPERIMENTAL
Intervention: Auto‐Mixer(®)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Manual intervention
Number of subjects: 20
Study: 22121243

Group type: EXPERIMENTAL
Intervention: Numerical and visual absolute effectiveness information
Number of subjects: 638

Group type: COMPARATOR
Intervention: Standard numerical effectiveness information
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Short-term quit rate (1-month)
Number of subjects: 638

Group type: COMPARATOR
Intervention: Long-term quit rate (12-month)
Number of subjects: 638
Study: 20615235

Group type: EXPERIMENTAL
Intervention: Community pharmacy adherence intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 17828094

Group type: EXPERIMENTAL
Intervention: Low‐intensive broad band electromagnetic radiation of the HFF‐range
Number of subjects: 0
Study: 16047528

Group type: EXPERIMENTAL
Intervention: Brief physician advice (two 10- to 15-minute counseling sessions)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 158
Study: 12048631

Group type: EXPERIMENTAL
Intervention: Endoscopic hemostasis with hypertonic saline and epinephrine (HSE) injection (n = 14)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Endoscopic hemostasis with hemoclipping or band ligation (n = 16)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Medical treatment (n = 46)
Number of subjects: 76
Study: 10637678

Group type: EXPERIMENTAL
Intervention: Multimodal Treatment (specifics not provided)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 7778548

Group type: EXPERIMENTAL
Intervention: Enalapril (2.5 to 10 mg twice daily)
Number of subjects: 734

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 734
Study: 2389694

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg every 6 hours for 6 days)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nadolol (80 mg daily for 7 days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Comparison of heart rate response after nadolol withdrawal
Number of subjects: 8
Study: 372609

Group type: EXPERIMENTAL
Intervention: Ticrynafen
Number of subjects: 28

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 28
Study: 30601976

Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG) monotherapy
Number of subjects: 158

Group type: COMPARATOR
Intervention: Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC)
Number of subjects: 158
Study: 28520484

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 436

Group type: COMPARATOR
Intervention: Cancer screening comparison condition
Number of subjects: 436
Study: 25552279

Group type: EXPERIMENTAL
Intervention: Standardised, concentrated added macronutrients parenteral (SCAMP)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control PN
Number of subjects: 150
Study: 24088534

Group type: EXPERIMENTAL
Intervention: BCG plus single-dose rifampicin (SDR)
Number of subjects: 20000

Group type: COMPARATOR
Intervention: BCG only (Control)
Number of subjects: 20000
Study: 21418630

Group type: EXPERIMENTAL
Intervention: SBAR communication tool
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient safety card
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leaflet with information on common complications post-discharge
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All interventions combined
Number of subjects: 0
Study: 19549054

Group type: EXPERIMENTAL
Intervention: Nicotine patch plus active nicotine gum
Number of subjects: 96

Group type: COMPARATOR
Intervention: Nicotine patch plus placebo gum
Number of subjects: 96
Study: 17078777

Group type: EXPERIMENTAL
Intervention: Exercise group (n = 24)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Pre-randomization exercise beliefs
Number of subjects: 52
Study: 14745707

Group type: EXPERIMENTAL
Intervention: 1:5 dilution of smallpox vaccine
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: 1:10 dilution of smallpox vaccine
Number of subjects: 674

Group type: COMPARATOR
Intervention: Undiluted smallpox vaccine
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: All subjects who developed a vesicle after vaccination
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: Larger lesion size and fever after vaccination
Number of subjects: 674
Study: 11328240

Group type: EXPERIMENTAL
Intervention: Morning bright light therapy (2500 lux)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Afternoon bright light therapy (2500 lux)
Number of subjects: 30
Study: 9002010

Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 9

Group type: COMPARATOR
Intervention: Water
Number of subjects: 9
Study: 7924594

Group type: EXPERIMENTAL
Intervention: Combined radiotherapy plus chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy and chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-FU given as continuous infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preoperative treatment
Number of subjects: 0
Study: 3131405

Group type: EXPERIMENTAL
Intervention: Cromolyn 20 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cromolyn 40 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cromolyn 60 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30053455

Group type: EXPERIMENTAL
Intervention: Highly malignant EEG patterns (suppression or burst‐suppression with or without discharges)
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: Benign EEG (continuous normal‐voltage background without malignant features)
Number of subjects: 950
Study: 26293981

Group type: EXPERIMENTAL
Intervention: Dentifrice without sodium lauryl sulfate (SLS) for 8 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Dentifrice with sodium lauryl sulfate (SLS) for 8 weeks
Number of subjects: 120
Study: 23838904

Group type: EXPERIMENTAL
Intervention: Two courses of S‐1/cisplatin (SC)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Four courses of S‐1/cisplatin (SC)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Two courses of paclitaxel/cisplatin (PC)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Four courses of paclitaxel/cisplatin (PC)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 83
Study: 22623075

Group type: EXPERIMENTAL
Intervention: Floseal
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control
Number of subjects: 196
Study: 20392316

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone gel
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study: 18039339

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 14709254

Group type: EXPERIMENTAL
Intervention: Ferric sulfate (FS) pulpotomy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Root canal therapy (RCT)
Number of subjects: 50